Korean firm PharmCADD has signed a Memorandum of Understanding (MoU) with the Indian Institute of Technology - Hyderabad (IITH), for co-developing new drugs and advancing platform technology PharmulatorTM on 24th July 2021. Under this MoU IIT-H will provide PharmCADD key members to conduct academic research in the field of AI and quantum calculation for new drug development.
PharmCADD has designed and optimised the mRNA sequence for developing COVID mRNA vaccine recently applied for IND (Investigational New Drug) to begin clinical trial 1/2a study in Korea. Based on this experience PharmCADD expanding a vaccine developing platform technology with IIT-H resources.
Sources : The Hindu